EMD SERONO

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Pimasertib once daily
Drug: SAR245409 placebo
Drug: Pimasertib twice daily
Drug: Pimasertib placebo
Drug: SAR245409

First Posted Date: 2013-09-06

Last Posted Date: 2018-12-12

Lead Sponsor: EMD Serono

Target Recruit Count: 65

Registration Number: NCT01936363

Locations: 🇪🇸
Research site, Valencia, Spain

Adherence Trial With MS LifeLines ® Services

Terminated

Conditions: Multiple Sclerosis
Relapsing-Remitting

Interventions: Other: Standard Services of Group A (Group A1)
Other: Customized Services of Group A (Group A2)
Other: Group B

First Posted Date: 2013-07-23

Last Posted Date: 2015-02-02

Lead Sponsor: EMD Serono

Target Recruit Count: 306

Registration Number: NCT01905527

Locations: 🇺🇸
Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Phase 2

Completed

Conditions: N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

Interventions: Drug: Pimasertib
Drug: Dacarbazine

First Posted Date: 2012-09-26

Last Posted Date: 2018-01-05

Lead Sponsor: EMD Serono

Target Recruit Count: 194

Registration Number: NCT01693068

Locations: 🇬🇧
Research Site, Southampton, United Kingdom
🇩🇪
Research site, München, Germany
🇺🇸
Please contact the US Medical Information in, Rockland, Massachusetts, United States

A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee

Phase 2

Terminated

Conditions: Cartilage Injury of Knee

Interventions: Drug: Sprifermin (AS902330)
Drug: Placebo

First Posted Date: 2012-09-21

Last Posted Date: 2017-01-13

Lead Sponsor: EMD Serono

Target Recruit Count: 1

Registration Number: NCT01689337

Tecemotide (L-BLP25) in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Radiation therapy
Drug: Goserelin
Drug: Cyclophosphamide
Drug: Tecemotide (L-BLP25)

First Posted Date: 2011-12-21

Last Posted Date: 2018-03-09

Lead Sponsor: EMD Serono

Target Recruit Count: 28

Registration Number: NCT01496131

Locations: 🇺🇸
Please Contact US Medical Information, Rockland, Massachusetts, United States

MSC2015103B in Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: MSC2015103B

First Posted Date: 2011-10-17

Last Posted Date: 2017-05-08

Lead Sponsor: EMD Serono

Target Recruit Count: 28

Registration Number: NCT01453387

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Atacicept Demonstrating Dose RESponSe

Phase 2

Withdrawn

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Atacicept
Drug: Placebo

First Posted Date: 2011-09-26

Last Posted Date: 2013-08-21

Lead Sponsor: EMD Serono

Registration Number: NCT01440231

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Melanoma
Locally Advanced Solid Tumor
Breast Cancer
Non Small Cell Lung Cancer
Metastatic Solid Tumor
Colorectal Cancer

Interventions: Drug: MSC1936369B (pimasertib)
Drug: SAR245409 (PI3K and mTOR inhibitor)

First Posted Date: 2011-07-11

Last Posted Date: 2017-03-07

Lead Sponsor: EMD Serono

Target Recruit Count: 146

Registration Number: NCT01390818

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States

and more 4 locations

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: Pimasertib
Drug: Temsirolimus

First Posted Date: 2011-06-22

Last Posted Date: 2018-07-30

Lead Sponsor: EMD Serono

Target Recruit Count: 33

Registration Number: NCT01378377

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
For Recruiting Locations in the US contact US Medical Information in, Rockland, Massachusetts, United States

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

Phase 1

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Atacicept

First Posted Date: 2011-06-09

Last Posted Date: 2013-10-22

Lead Sponsor: EMD Serono

Target Recruit Count: 1

Registration Number: NCT01369628

Locations: 🇺🇸
EMD Serono Inc., One Technology Place, Rockland, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy